HC Wainwright Weighs in on Jasper Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:JSPR)

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Stock analysts at HC Wainwright issued their Q1 2024 earnings estimates for shares of Jasper Therapeutics in a research report issued on Monday, May 6th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($1.43) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($5.00) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q2 2024 earnings at ($1.36) EPS, Q3 2024 earnings at ($1.41) EPS, Q4 2024 earnings at ($1.56) EPS, FY2024 earnings at ($5.75) EPS, FY2025 earnings at ($5.19) EPS, FY2026 earnings at ($5.42) EPS, FY2027 earnings at ($6.28) EPS and FY2028 earnings at ($6.25) EPS.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Monday, March 4th. The company reported ($1.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.15.

Other equities analysts have also recently issued reports about the company. TD Cowen initiated coverage on Jasper Therapeutics in a report on Monday, March 18th. They issued an “outperform” rating on the stock. Evercore ISI started coverage on Jasper Therapeutics in a research note on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 price objective on the stock. Royal Bank of Canada assumed coverage on Jasper Therapeutics in a research report on Thursday, March 28th. They set an “outperform” rating and a $70.00 price objective on the stock. Finally, Oppenheimer reissued an “outperform” rating and issued a $80.00 target price on shares of Jasper Therapeutics in a report on Thursday, March 7th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $64.29.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock opened at $21.42 on Thursday. The stock has a market capitalization of $322.59 million, a PE ratio of -3.45 and a beta of 2.25. Jasper Therapeutics has a 1-year low of $4.00 and a 1-year high of $31.01. The company’s fifty day simple moving average is $25.52 and its 200-day simple moving average is $15.12.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JSPR. Ieq Capital LLC purchased a new stake in shares of Jasper Therapeutics in the fourth quarter worth about $43,000. Summit Trail Advisors LLC bought a new stake in Jasper Therapeutics in the 3rd quarter worth approximately $46,000. Forefront Analytics LLC raised its holdings in shares of Jasper Therapeutics by 59.7% during the 3rd quarter. Forefront Analytics LLC now owns 110,792 shares of the company’s stock worth $78,000 after acquiring an additional 41,425 shares in the last quarter. Cowen AND Company LLC purchased a new stake in shares of Jasper Therapeutics during the 3rd quarter worth approximately $140,000. Finally, Monaco Asset Management SAM bought a new position in shares of Jasper Therapeutics during the 4th quarter valued at approximately $197,000. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.